Humana Lawsuit 2026: What the Medicare Advantage Star Ratings Case Means for You
Quick Answer
- The Humana lawsuit is a real, active federal securities fraud case in Delaware federal court, not yet settled.
- No settlement fund exists yet, so per-share or per-person payouts are not yet determined.
- No claim window is open right now. The case is in discovery, with no confirmed trial date.
If you searched “Humana lawsuit” because of a news alert, a drop in your Humana stock value, or a headline about Medicare Advantage star ratings, here’s the direct answer. Humana is facing two connected legal fights, one from investors, one that Humana itself filed against the federal government. Neither has produced a settlement or a payout yet.
The investor case, formally called In re Humana Inc. Securities Litigation, cleared a major hurdle in April 2026 when a judge refused to throw it out. It centers on whether Humana misled shareholders about the same star ratings collapse that has cost the company an estimated $1 billion to $3 billion in Medicare bonus revenue. Separately, Humana has spent nearly two years suing the Centers for Medicare and Medicaid Services (CMS) over those ratings, and lost twice.
This article breaks down both cases, who is actually eligible for anything, and what to watch for next. One detail most coverage skips: the star drop wasn’t gradual. Humana went from 94% of its Medicare Advantage members in four-star-or-better plans in 2024 to just 20% for 2026.
The Facts
| Case | In re Humana Inc. Securities Litigation |
| Court | U.S. District Court, District of Delaware |
| Status | Motion to dismiss largely denied April 27, 2026; case now in discovery |
| Fund Size | Not yet confirmed, no settlement has been reached |
| Est. Per Person | Not yet determined |
| Claim Deadline | Not yet open, no claims process exists |
| Administrator | Not yet appointed |
| Proof Needed | Not yet determined, watch official case updates |
Is the Humana Lawsuit Real in 2026?
Yes, the Humana securities lawsuit is a real, active federal case, not a scam or a rumor.
It’s formally captioned In re Humana Inc. Securities Litigation, filed in the U.S. District Court for the District of Delaware and assigned to Judge Jennifer L. Hall. Multiple shareholder complaints, first filed in mid-2024, were consolidated into one amended complaint on November 20, 2024.
The defendants are Humana Inc., former CEO Bruce D. Broussard, and former CFO Susan M. Diamond. This isn’t a fringe filing from a single unhappy investor. The lead plaintiff is SEB, a major Swedish institutional investment fund, represented by Kessler Topaz Meltzer & Check, one of the larger plaintiff-side securities firms in the country.
Key Takeaway: The Humana lawsuit is a confirmed, court-docketed securities fraud case in active discovery, not a settled claim you can currently file for.
Is This the Same as the Humana Medicare Advantage Star Ratings Case Against CMS?
No, these are two separate lawsuits that share the same underlying facts.
One is Humana suing the federal government (CMS and HHS) to try to force a recalculation of its 2025 star ratings. The other is investors suing Humana itself, alleging the company misled them about the risk to those same ratings before the drop became public.
Here’s how they differ:
| Feature | Humana v. CMS/HHS | In re Humana Securities Litigation |
|---|---|---|
| Who sued whom | Humana sued the federal government | Investors sued Humana |
| Court | N.D. Texas, now 5th Circuit on appeal | D. Delaware |
| What’s at stake | Star ratings recalculation, bonus payments | Investor damages for alleged fraud |
| Status | On appeal, no ruling | In discovery |
| Consumer payout possible | No | Not yet, no settlement |
Neither case currently offers Medicare Advantage members a claim to file. Both are about money flowing between Humana, the government, and shareholders.
How Much Could Humana Investors Get in This Lawsuit?
Not yet determined. No settlement, judgment, or verdict has been reached in the securities case, so there is no confirmed per-share payout figure.
Securities fraud class actions like this one typically don’t produce a number until one of three things happens: the case settles, a jury reaches a verdict, or the court certifies a class and damages are calculated. None of those has occurred here as of September 2026.
What is confirmed is the scale of the alleged harm. Investors purchased Humana stock at what the complaint calls “artificially inflated prices” during a class period running from July 27, 2022, through October 1, 2024. A July 2026 investor notice from Schubert Jonckheer & Kolbe cited a roughly 22% stock decline tied to the disclosures at issue.
Any eventual recovery, if one happens, would be divided among class members based on how many shares or options they held and when they traded, not as a flat per-person check. Anyone telling you a specific dollar figure right now is guessing.
Who May Qualify as a Class Member?
You may be part of the proposed investor class if you meet specific trading criteria during the class period.
Based on the amended complaint, the proposed class includes people and institutions who:
- Purchased or otherwise acquired Humana Inc. (NYSE: HUM) common stock between July 27, 2022, and October 1, 2024
- Purchased Humana call options during that same window
- Sold Humana put options during that same window
The class has not been formally certified by the court yet, so this remains a proposed group. Institutional investors, pension funds, and individual retail shareholders can all potentially qualify if their trades fall in this window.
Key Takeaway: Only people who traded Humana stock or options during the specific July 2022 to October 2024 window are part of the proposed investor class, and even then, no payout process exists yet.
What Caused Humana’s Stock Price Drop?
Humana’s stock fell after investors learned the company’s Medicare Advantage business was under more strain than executives had disclosed.
The lawsuit alleges Humana downplayed how much post-pandemic “pent-up demand” for medical care was driving up costs. It also claims Humana concealed that internal cost-cutting, including staff reductions, was quietly damaging the departments responsible for keeping star ratings high.
A federal judge found the complaint plausibly alleged 42 separate false or misleading statements made by Humana executives. That ruling, issued April 27, 2026, found the company and its former CEO and CFO knew about the utilization spike and the star ratings risk while making public assurances that suggested otherwise.
Think of it like a store telling shoppers a return policy is unchanged right up until the day it quietly tightens the rules. The lawsuit argues Humana kept investors in the dark on a similar timeline.
Reality Check
No court, law firm, or settlement fund will ever text or email you out of nowhere asking for a fee to “release” your Humana lawsuit payout. There is no active claims process right now, so anyone asking for payment to file one is not legitimate. Filing a legitimate securities class claim, if one ever opens, is always free.
How to File a Claim or Join the Humana Lawsuit
There is no claim form to file yet because no settlement or judgment exists. If you believe you may be a class member, here’s what typically happens next in a case at this stage:
- Do nothing for now. No action is required to preserve rights in a class action unless you plan to opt out later.
- Save your trade records. Keep brokerage statements showing Humana stock or option trades between July 2022 and October 2024.
- Watch for a class certification ruling, which determines who is formally included.
- Watch for a settlement announcement or trial date, either of which would trigger an actual claims process.
- If a settlement happens, an administrator will typically mail or email notices with a claim form and deadline.
- File only through the official case website or court-approved administrator once one is named.
How to Check Your Humana Lawsuit Status
The fastest way to check status is to monitor the official Delaware federal court docket and the lead counsel’s case page.
Because no claims administrator has been appointed, there’s no member portal or hotline yet. Court filings and law firm case-update pages, like those from Kessler Topaz Meltzer & Check as lead counsel, are currently the most reliable sources for developments in the securities case.
For the separate CMS appeal, the Fifth Circuit’s public docket (case No. 25-11302) shows filing activity and, eventually, oral argument scheduling.
Key Takeaway: With no settlement administrator yet named, official court dockets and lead counsel updates are the only verified sources for current case status.
What Is the Latest Update on the Humana Securities Lawsuit?
The most recent major development is the court’s decision to let the case proceed past the motion to dismiss stage.
On April 27, 2026, Judge Jennifer L. Hall issued an order substantially denying Humana’s motion to dismiss. The ruling found the lead plaintiff had adequately pled both falsity and materiality across all 42 challenged statements. On June 10, 2026, Humana filed its formal Answer to the amended complaint. The case is now in the discovery phase, meaning both sides are exchanging documents and evidence ahead of any potential trial or settlement talks.
What Happened to Humana’s Star Ratings Lawsuit Against CMS?
Humana lost its fight against CMS twice in the same federal court before appealing.
Humana first sued in October 2024, arguing CMS had acted arbitrarily in downgrading its star ratings based on a small number of test customer service calls involving interpreter availability. A Texas judge dismissed that case without prejudice in July 2025 on procedural grounds. Humana refiled, and the same judge, Reed O’Connor, dismissed it a second time, with prejudice, on October 14, 2025, ruling CMS acted lawfully.
Is Humana Appealing Its Star Ratings Case?
Yes. Humana filed a notice of appeal to the Fifth Circuit Court of Appeals on November 25, 2025.
The appeal, docketed as case No. 25-11302, does not yet have a ruling as of September 2026. Court filings show Humana cited a related favorable ruling in a similar Clover Health case in a supplemental filing on June 2, 2026, and the appeal remains pending argument. A win here would not create a consumer payout. It could restore some of Humana’s lost bonus revenue and potentially affect the securities case’s damages theory.
What Is the Humana Medicare Advantage Lawsuit About?
At its core, this is a dispute over how CMS calculates the star ratings that determine billions in insurer bonus payments, and what Humana told investors about the risk.
Humana’s Medicare Advantage star average fell from 4.37 in 2024 to 3.63 for 2025, the steepest drop of any major insurer that year. Its largest single contract, H5216, which covers close to 45% of Humana’s Medicare Advantage membership, dropped from 4.5 stars to 3.5 stars. Only plans rated four stars or higher qualify for CMS quality bonus payments, so this drop carries direct financial consequences.
Why Did Humana’s Star Ratings Drop?
CMS downgraded Humana partly over three test phone calls it judged unsuccessful during an interpreter-availability accuracy study, plus broader shifts in scoring cut points across measures.
Humana argued CMS moved cut points, the thresholds separating star levels, abruptly and without adequate explanation. CMS and the courts disagreed, finding the agency’s process lawful. Meanwhile the securities lawsuit adds another layer, alleging internal cost-cutting at Humana weakened the customer service infrastructure the ratings measure in the first place.
It’s a bit like a restaurant getting a lower health inspection score, then getting sued by investors for insisting beforehand that the kitchen was in great shape.
Key Takeaway: The star ratings drop stems from disputed CMS scoring methodology, while the securities case adds allegations that Humana’s own cost-cutting contributed to the decline it didn’t fully disclose.
What Are the Related Humana Shareholder Derivative Lawsuits?
Several related derivative lawsuits are pending in the Western District of Kentucky, separate from the Delaware securities case.
These cases, including actions with docket numbers 3:24-cv-00418, 3:24-cv-00590, 3:24-cv-00630, and 3:25-cv-00171, allege Humana’s board and executives breached fiduciary duties tied to the same star ratings and utilization issues. Court filings from October 2025 show these Kentucky cases have been paused, with parties agreeing to wait for the outcome of the Delaware securities case before proceeding further.
What Happens If Humana Loses the Lawsuit?
If Humana loses or settles the securities case, affected investors could eventually see a distributed payout, though the amount and timeline remain unknown.
A loss or settlement would not directly compensate Medicare Advantage members or change your coverage. It could result in monetary damages paid to the certified investor class, and it could increase pressure on Humana’s board regarding the related derivative claims. A win for Humana at the motion-to-dismiss or trial stage would end the case with no payout at all.
What Happens Next
- Ongoing through late 2026: Discovery continues in the Delaware securities case, with both sides exchanging evidence.
- Pending, no date confirmed: Fifth Circuit oral argument and ruling on Humana’s appeal against CMS.
- Expected in coming months: Possible motion for class certification in the securities case.
- TBD: Any settlement talks, mediation, or trial scheduling order.
- TBD: Resolution or continued pause of the related Kentucky derivative lawsuits.
Frequently Asked Questions
Is the Humana lawsuit legitimate or a scam?
It’s a legitimate, court-docketed federal securities fraud case in the District of Delaware.
There is no active claims process, so anyone contacting you asking for money to join it is not part of any official process.
How much is the Humana Medicare Advantage lawsuit settlement?
There is no settlement yet, so no dollar amount exists.
The case is still in discovery following an April 2026 ruling that let most claims proceed.
Who can join the Humana securities lawsuit?
People who bought Humana stock or call options, or sold put options, between July 27, 2022, and October 1, 2024, may fall within the proposed class.
The class has not been formally certified by the court.
Does the Humana lawsuit affect my Medicare Advantage coverage?
No, this litigation does not change your current Medicare Advantage benefits or enrollment.
It concerns investor damages and a separate dispute over insurer bonus payments from CMS.
When will the Humana lawsuit be decided?
No trial date or resolution date has been confirmed as of September 2026.
The case is in discovery, and no settlement or verdict has been reached.
Did Humana admit any wrongdoing?
No, Humana has not admitted wrongdoing.
The company filed an Answer to the amended complaint on June 10, 2026 and continues to contest the allegations.
What is the difference between the CMS case and the securities case?
The CMS case is Humana suing the federal government over star ratings methodology.
The securities case is investors suing Humana over what it told them about that same ratings risk.
Where can I get real updates on this case?
Official federal court dockets in Delaware and the Fifth Circuit, plus lead counsel case pages, currently offer the most reliable updates.
No settlement administrator or claims website exists yet.
If you hold or held Humana stock during the class period, the most useful step right now is simply organizing your brokerage records. Watch the Delaware docket for a class certification ruling before assuming anything about eligibility or payout.
The single date to remember is July 27, 2022 through October 1, 2024, the class period at the center of the entire case.
